View Full List
Standard & Poors 500
New York Composite
Merck Kgaa ADR
Streaming Delayed Price
Updated: 3:49 PM EST, Jan 21, 2022
Add to My Watchlist
Stories about Merck Kgaa ADR
Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing
January 21, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid continued questions about the profitability and competitive advantages of Palantir, PLTR stock remains a sell. The post Despite...
Stocks to Sell
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
November 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary ...
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
September 30, 2021
Merck KGaA(OTC: MKGAF) andGlaxoSmithKline Plc(NASDAQ: GSK) haveended their $4 billion collaborationon ...
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
September 21, 2021
Nektar Therapeutics Inc(NASDAQ: NKTR)has entered into a new oncology clinical collaborationwithMerck ...
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
August 24, 2021
Merck KGaA's(OTC: MKGAF) announced that aPhase 2 trial of bintrafusp alfa had been discontinued, as an independent ...
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
June 01, 2021
Sutro Biopharma Inc(NASDAQ: STRO)has received a milestone paymentunder its collaboration and license agreement with ...
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
June 01, 2021
Immutep Limited(NASDAQ: IMMP) has announced anew collaboration and supply agreementwith Germany-basedMerck ...
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
May 14, 2021
Vera Therapeutics Inchaspriced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, ...
MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript
May 13, 2021
MKKGY earnings call for the period ending March 31, 2021.
UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
May 10, 2021
England’s drug-cost watchdog has shown a cold-shoulder toPfizer Inc(NYSE:PFE) andMerck ...
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
April 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
April 07, 2021
Novartis AG(NYSE:NVS) hasstruck a dealwith UK-based Artios Pharma to access DNA damage response (DDR) targets ...
Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma
March 18, 2021
Exelixis Inc(NASDAQ:EXEL) hasannounced a clinical trial collaborationand supply agreement with Germany's ...
Germany's Merck Invests In French Facility For Single Use Products
March 17, 2021
Germany’sMerck KGaA(OTCMKT: MKGAF) willinvest €25 millionin its Molsheim, France facility to make ...
Why Precigen Stock Is Skyrocketing Today
October 09, 2020
A big partner is increasing its stake in the biopharmaceutical company.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Terms and Conditions